The battle for the first-line treatment market for urothelial cell carcinoma (bladder cancer) is heating up amongst anticancer drugs.

In addition to the PD-L1 immuno-oncology drug Bavencio (avelumab), which is already being reimbursed in Korea, the PD-1 immuno-oncology drug Opdivo (nivolumab) in combination with cisplatin and gemcitabine, and the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) in combination with the PD-1 immuno-oncology drug Keytruda (pembrolizumab) have entered the market one after another.

The Opdivo and the ‘Padcev+Keytruda’ combination have garnered particular attention due to their recent almost simultaneous indication expansions. It remains to be seen